More on IBRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-14.3% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

ImmunityBio (NQ:IBRX)
Delayed: 7.68 -0.38 (4.71%)
Prev. Close $8.06  
Open$7.87 
52 Wk High$ 
52 Wk Low$ 
Day High$7.89 
Day Low$7.65 
P/E N/A  
EPS$ 
Volume5,191,261 

Friends, Peers and Foes (?): FATE, ALNY, ARVN, ARWR, CAPR (more...)

Sep 1, 2026 09:07 AM Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
Aug 10, 2026 09:01 AM ImmunityBio names former World Bank president Jim Yong Kim as vice chairman
Aug 10, 2026 09:00 AM ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
Aug 6, 2026 06:51 PM Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
Aug 4, 2026 07:46 AM Form 10-Q ImmunityBio, Inc. For: Jun 30
Aug 4, 2026 07:38 AM ImmunityBio, Inc. (IBRX) Misses Q2 EPS by 14c
Aug 4, 2026 07:36 AM Form 8-K ImmunityBio, Inc. For: Aug 04
Aug 4, 2026 07:30 AM ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
Jul 30, 2026 05:20 PM Form 8-K ImmunityBio, Inc. For: Jul 29
Jul 30, 2026 04:53 AM UAE approves ImmunityBio's Anktiva for bladder and lung cancer
View All Articles

Entities mentioned with ibrx

View All Entities